A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing

S. Udhaaya Kumar, N. Madhana Priya, S. R. Nithya, Priyanka Kannan, Nikita Jain, D. Thirumal Kumar, R. Magesh, Salma Younes, Hatem Zayed, C. George Priya Doss

Received: 25 August 2020 / Accepted: 16 March 2021 / Published online: 27 March 2021
© King Abdulaziz City for Science and Technology 2021

Abstract
Coronavirus disease (COVID-19) pandemic is instigated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of March 13, 2021, more than 118.9 million cases were infected with COVID-19 worldwide. SARS-CoV-2 is a positive-sense single-stranded RNA beta-CoV. Most COVID-19 infected individuals recover within 1–3 weeks. Nevertheless, approximately 5% of patients develop acute respiratory distress syndrome and other systemic complications, leading to death. Structural genetic analyses of SARS-CoV-2 have shown genomic resemblances but a low evolutionary correlation to SARS-CoV-1 responsible for the 2002–2004 outbreak. The S glycoprotein is critical for cell adhesion and the entrance of the virus into the host. The process of cell entry uses the cellular receptor named angiotensin-converting enzyme 2. Recent evidence proposed that the CD147 as a SARS-CoV-2’s potential receptor. The viral genome is mainly held by two non-structural proteins (NSPs), ORF1a and ORF1ab, along with structural proteins. Although NSPs are conserved among the βCoVs, mutations in NSP2 and NSP3 may play critical roles in transmitting the virus and cell tropism. To date, no specific/targeted anti-viral treatments exist. Notably, more than 50 COVID-19 candidate vaccines in clinical trials, and a few being administered. Preventive precautions are the primary strategy to limit the viral load transmission and spread, emphasizing the urgent need for developing significant drug targets and vaccines against COVID-19. This review provides a cumulative overview of the genomic structure, transmission, phylogeny of SARS-CoV-2 from Indian clusters, treatment options, updated discoveries, and future standpoints for COVID-19.

Keywords COVID-19 · Drug repurposing · SARS-CoV-2 · SARS-CoV-2 genome · COVID-19 therapeutics · Vaccines · COVID-19 molecular diagnosis · Remdesivir · Hydroxychloroquine · Protease · India

Introduction
The coronavirus disease (COVID-19), which started in Wuhan, China, has spread across the world, affecting 218 countries and territories (Huang et al. 2020a; Wang et al. 2020b; Liu et al. 2020; World Health Organization 2020). The rapid dissemination of the virus is mainly due to its adaptation to human transmission by affecting the angiotensin-converting enzyme 2 (ACE2) receptor, thus leading to the rapid transmission of the pathogen in human communities. The identification of the SARS-CoV-2 virus was carried out using Next Generation Sequencing (NGS), and it is currently the most commonly used method to diagnose COVID-19 (Kumar et al. 2020). The widespread dissemination of the virus in India is because of its unique geographic, cultural, and social features. The country has a vast physical and cultural diversity, a large population, and a well-developed network of transportation, which can lead to the rapid spread of the virus. The virus is transmitted primarily through respiratory secretions, and the virus transmission is possible between human hosts through airborne droplets and direct contact. The virus may also be transmitted through contaminated fomites, such as hands, surfaces, and other objects (Bhakoo et al. 2020). India has reported a significant number of COVID-19 cases, and over 100 million infected cases have been reported until now (Department of Biotechnology, Government of India 2020). Significant challenges with respect to the rapid dissemination of the virus in India include the socio-economic disparities in the country, the health care system of the country, and the ability of the country to adopt necessary precautionary measures. The government of India has been taking several measures to contain the spread of the virus, such as lockdowns, social distancing, and other preventive measures.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the infection. The virus mainly affects the respiratory system leading to flu-like symptoms, including high temperature, coughing, and in more severe cases, breathing difficulty (Zou et al. 2020). Most patients recover in a period of 1–3 weeks; however, approximately 5% develop severe symptoms that may progress to acute respiratory distress syndrome (ARDS) and respiratory failure, which may cause death. Besides, in patients at high risk, COVID-19 may lead to systemic inflammation, putting patients at risk of sepsis, cardiac injury, and organ dysfunction (Wang et al. 2020a). Older people (>60 years) and people with other morbidities are at a higher risk of mortality (Wang et al. 2020a).

Coronaviruses (CoVs) belong to the family of Coronaviridae that encompass four genera that include alpha-, beta-, gamma-, and delta-CoVs. Alpha- and beta-CoVs infect mammals and humans, while gamma-CoVs infect birds and delta-CoVs infect birds and mammals. The two most known types of human CoVs are the beta-CoV OC43 and the alpha-CoV 229E, both of which typically cause minor disease conditions, usually mild upper respiratory diseases that are self-limiting in individuals with a tolerable immune system (Sahin et al. 2020). Other human coronaviruses include the Middle East respiratory syndrome coronavirus (MERS-CoV, 2013), SARS-CoV-1 (2002), and the novel SARS-CoV-2, all of them belong to beta-CoVs, are transmitted through zoonotic transmission (from animals to humans), then spread among humans via close contact causing severe diseases (Li et al. 2020a). Genomic characterization revealed that the sequences of SARS-CoV-2 exhibit high homology with that of the previously identified SARS-CoV-1 and weaker homology with MERS-CoV (Jaimes et al. 2020).

Nevertheless, the clinical and epidemiological characteristics of SARS-CoV-2 are not precisely the same as that of SARS-CoV-1. SARS-CoV-2 is highly transmittable compared to SARS-CoV-1, with a 2.6 primary reproduction number (R0) of spread, implying that the number of SARS-CoV-2 positive cases increases exponentially (Hellewell et al. 2020). Moreover, SARS-CoV-2 has lower-level mortality compared to SARS-CoV-1. CoVs are enveloped viruses and have the most abundant RNA viral genome, with a length ranging from 25 to 31 kb. SARS-CoV-2 is a spherical enveloped consisting of single-stranded positive-sense RNA linked with a nucleoprotein inside a capsid comprising a matrix protein. The envelope has glycoprotein projections in a bear club-shape. The viral diameter is approximately 150–160 nm. The SARS-CoV-2 exhibits high sequence similarity with the bat-SL-CoVZC45

**Genomic structure**

CoVs are known to possess the largest genomes among all known RNA viruses, with a length ranging from 25 to 31 kb. SARS-CoV-2 is a spherical enveloped consisting of single-stranded positive-sense RNA linked with a nucleoprotein inside a capsid comprising a matrix protein. The envelope has glycoprotein projections in a bear club-shape. The viral diameter is approximately 150–160 nm. The SARS-CoV-2 exhibits high sequence similarity with the bat-SL-CoVZC45.
and bat-SL-CoVZXC2 (≈ 88% and 87%, respectively) while being less similar to SARS-CoV-1 and MERS-CoV (≈ 79% and 50%, respectively) (Lu et al. 2020).

A typical CoV genome contains protein-encoding domains (5’ non-basic) consisting of two-third of genome replicase genes and 3’ structural and non-essential accessory protein-coding domains (Masters 2006). The cells that contain the virus produce seven to nine viral-specific messenger RNAs with ends of 3’ co-terminal (Masters 2006). The mRNAs’ entirety conveys similar master sequences that span 70–90 nucleotides at the end of 5’ (Lai et al. 1984, 1985). At their 5’ ends, CoVs mRNAs have a leader sequence, which is common among them (Spaan et al. 1983), which comprises a transcription regulatory sequence (TRS-L) at the 3’ end that arranges part of the signal for transcription of the sub-genomic mRNA (Budzilowicz et al. 1985). The transcriptional regulatory sequences (TRSs) of all CoVs incorporated the conserved core sequences (CS), consisting of 6–8 nucleotides, along with 5’ and 3’ flanking sequences (Sola et al. 2005). Beta-CoVs comprise 5’-UCUAAAC-3’, a heptameric consensus sequence. Replication occurs shortly after the virus enters the infective cell, followed by virion transfection via the generation of entire-length genomic and sub-genomic intermediate negative strands (Yount et al. 2005). Beta-CoVs comprise 5’-UCUAAAC-3’, a heptameric consensus sequence. Replication occurs shortly after the virus enters the infective cell, followed by virion transfection via the generation of entire-length genomic and sub-genomic intermediate negative strands (Yount et al. 2000). There is a minimum of 6 open reading frames (ORFs) in the CoV structures’ genomic and subgenomic regions. The SARS-CoV-2 genome contains 14 ORFs. The most significant part of the whole genome length is known to be the ORFa/b, the first of the ORFs, which encodes NSP1-16 (non-structural proteins), apart from Gamma-CoVs with the absence of NSP1. The polypeptides pp1a and pp1ab produced by − 1 frameshift among ORF1a and ORF1b are processed virally determined main protease (Mpro) or chymotrypsin-like protease (3CLpro) and other minor proteases into 16 NSPs (Masters 2006).

As revealed by the whole-genome sequence alignment of the NSP-coding regions, there is approximately 58% identity among the varying CoV strains. About 43% identity in the structural protein-coding regions implies that NSPs form the genome’s conserved regions, while structural proteins are more diverse (Chen et al. 2020). The NSPs aid in replication of the genome, proteolytic cleavage, and development of sub-genomic mRNA (14–16 final products prepared for coronaviruses) are inscribed on gene one inside the 5’-proximate, which is two-third; whereas the structural proteins are inscribed on eight-nine genes inside the 3’-proximate, which is one-third of the coronavirus genome. The structural genes are positioned in the order of 5’ to 3’; they encode for viral proteins that include spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Overall, the SARS-CoV-2 genome is about 25–31 kb in size with a spherical structure containing 9,860 amino acids. The genome encodes for 13 ORF’s, out of which the first one-third codes for NSPs, and the remaining make up the structural proteins. The CoV strains’ identity varies in terms of the protein structure, where structural proteins show diverse structural characteristics.

SARS-CoV-2 detection

Nucleotide detection assays (NDA) such as Next Generation Sequencing (NGS) and RT-PCR detection technologies were implemented to detect SARS-CoV-2 (Shey et al. 2020; NGS 2020, p. 19). Compared to the sequencing/NGS technologies, RT-PCR remains a cheaper method to detect SARS-CoV-2 infection (Ai et al. 2020). The results can be achieved by assessing the expectorated sputum, bronchoalveolar lavage, or endotracheal aspirate samples acquired from the respiratory tracts (Lambert-Niclot et al. 2020). The tests are repeated for re-verification in positive results and negative cases with strong clinical suspicions (Hassan et al. 2020). The genetic material obtained from the mucus or salivary samples is amplified in the laboratory using RT-PCR. After retrieving a sufficient amount of the genetic material, the conserved regions of the CoV are determined. The probes have been used based on existing gene sequences published on Virological.org by the Shanghai Public Health Clinical Center & Public Health School, Fudan University, Shanghai, China, and subsequently confirmed by other labs. In the COVID-19 positive cases, the tests are repeated to confirm the viral particles’ clearance before the patient’s discharge. The testing for the infection will differ based on the country (Dong et al. 2020). Several biosensors have been developed and identified for early SARS-CoV-2 detection (Behera et al. 2020).

Commercial NDA such as SARS-CoV-2 RNA detection kits was discovered, and nearly 37 commercial detection kits were approved by FDA (Health 2020). Non-commercial NDA, such as Loop-mediated isothermal amplification (LAMP) and RT-LAMP, is recognized as an optimistic method than PCR. It provides more sensitivity, specificity, product yield, and reaction efficiency (Ji et al. 2020). Consequently, several other detection methods have been employed, such as NP antigen detection assay, Antibody detection assays targeting SP and NP viral proteins (Ejazi et al. 2020; Li et al. 2020c; Guo et al. 2020). CT findings have been used controversially as a surrogate diagnostic test. Chest CT has a vital role in diagnosing COVID-19. COVID-19 occurs with pneumonia symptoms in the initial stage, including dry cough, fever, chest congestion, and fatigue. Therefore, chest scan aids in the assessment of the disease extent condition and its follow-ups as it shows the patchy or diffuse asymmetric airspace opacities, which is an acute symptom of COVID-19. The initial scans showed a bilateral lung development pattern for around 40 patients out of 41
ICU patients (Hosseiny et al. 2020). The multifocal peripheral ground glass imaging results are highly suspicious of COVID-19, which might show a rapid change in a short duration (Table 2) (Li et al. 2020d).

Structural proteins

SARS-CoV-2 encompasses four types of structural proteins, namely S, E, M, and N proteins. These four structural proteins share high sequence identity to that of SARS-CoV-1 and MERS-CoV. It is incorporated with hemagglutination (HE) and glycoprotein acetyl esterase, making SARS-CoV-2 distinct from other CoVs (Cascella et al. 2020). The S proteins lie in the outermost sessions of the viral particle, ACE2, which is known to have an essential part in the action of transmembrane receptor recognition, which is used by the CoVs to make an entry into the host cell. Therefore, the host specificity and infectious nature of CoVs are determined chiefly by the S proteins (Letko et al. 2020). Among all proteins within the virus structure, M protein is perhaps the most effective and is present in considerably various extents; it also provides the virus’s shape. Figure 1 depicts the SARS-CoV-2 mechanism in the host cell.

On the other hand, inside the virion, E protein exists in the least quantity and helps release the infected cells’ viral particles (Nal et al. 2005; Ashour et al. 2020). Simultaneously, the N protein attaches to the viral RNA, which is obligatory during viral assembly for wrapping the viral RNA into the viral components (Parameshwar et al. 2020). On the beta-CoV surface, the HE is located. It is similar to the influenza virus hemagglutinin. It provokes acetyl-esterase activity, characteristics of HE might enhance the pathogenesis and entrance of CoVs that involve proteins at its viral structure (Klaussegger et al. 1999). CoVs use the S proteins to initiate the binding with the host cell. The binding activation is carried out by furin, an enzyme in several humans’ organs, including the lungs, small intestine, and liver (Callaway et al. 2020). The S protein and the furin enzyme activation are not the only factors; other human cells’ elements make them more vulnerable to new SARS-CoV-2 infection. In human cells, it was shown that the S protein needs to bind to ACE2, which allows SARS-CoV-2 to cause infection in human cells (Wrapp et al. 2020).

Experts suggested that furin inhibitors might be an effective therapeutic against COVID-19. Meanwhile, it is also recommended that blocking ACE2 might also be another feasible solution, stopping the CoV from cell entry (Coutard et al. 2020). In CoV, the RNA genome is enclosed in the N protein, further embedded into an envelope (Fan et al. 2005; McBride et al. 2014). The structural and NSPs are produced by sub-genomic + sense RNAs translation. After the formation of viral RNA components, the assembling of structural viral protein occurs in the virions. The budding and viral assembly occur in the endoplasmic reticulum-Golgi intermediate (Zhang et al. 2020).

Common drug targets

Spike protein (S)

The S protein is a 150 KDa class I fusion transmembrane protein found in its outer portion. The protein contains an alpha-helical coiled structure and is highly glycosylated as it includes N-glycosylation sites from 21 to 35. It gathers as trimers giving a crown shape (corona; crown in Latin). They usually contain two N-terminal spaces labeled S1 that are liable for binding the receptor and a C-terminal S2 space essential for fusion. The S1 spaces comprise two sub-domains: N-terminal space and C-terminal space. Both subdomains work as receptor restricting spaces and tie an assortment of protein and sugar (Robson 2020). The SARS-CoV-2’s S protein attaches ten to multiple times more sturdy to the receptor ACE2 in people in contrast to that of the S protein of SARS-CoV-1 infection from 2002, which is liable for the simple spread of COVID-19 from individual to individual than different CoVs. The antibodies used against SARS-CoV-1 could not bind to the new SARS-CoV-2 S protein successfully; therefore, the vaccines or the antibody-based treatment should be unique for COVID-19. It is noteworthy that the proteases in host cells cleave the S1 domain instantly after the upstream of the S2 fusion peptide, which is anticipated to be the reason for protein activation through irreversible conformational changes (Walls et al. 2020).

Envelope protein (E)

The E protein is a small integral membrane protein but perhaps the most enigmatic. It is primarily expressed in infected cells during the replication cycle, and only a minute fraction is integrated with the virus envelope. The E protein is essential in virus assembly and maturation (Schoeman and Fielding 2019). They have three domains: hydrophilic amino acid terminus consist of 7–12 amino acids, the transmembrane hydrophobic domain containing 25 amino acids, and a long C-terminal end with the majority of proteins. The transmembrane domain (TMD) comprises two nonpolar, impartial amino acids: Leu and Val give solid hydrophobicity to E-protein. The central region [TMD] is uncharged, which is flanked towards one side by the amino acid negatively charged and on the opposite side via carboxy end of variable charges, which together give the E peptide gross net charge of zero (Schoeman and Fielding 2019). The E protein of SARS-CoV contains a restricting theme called postsynaptic thickness protein 95 (PSD95), Drosophila plate enormous tumor silencer (Dlg1), Zonula occludes-1 protein.
| Method                                      | Instrument                                      | Use                                                                 | Disadvantage                                                                 |
|--------------------------------------------|-------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|
| Nucleotide detection assay (Shey et al. 2020; NGS 2020, p. 19) | DNA sequencing                                  | To identify novel mutations and the evolution of SARS-CoV-2 isolates | Time-consuming, high manpower, Expensive                                    |
|                                            | RT-PCR                                          | High detection sensitivity detect more target regions               | Risk of eliciting false-negative and false-positive results                |
|                                            |                                                  |                                                                    | False-negative results may occur by mutations in the primer and probe target |
| Virus particle detection (Ji et al. 2020)  | Immunoassay                                     | Utilizes fabricate graphene-based field-effect-transistor (FET) biosensors | High signal noise ratio                                                     |
| NP antigen detection assay (Lambert-Niclot et al. 2020) | Mass spectrometric analysis, ELISA, and quantum dot-based lateral flow assay | Detected within three days of onset of fever, NP expression is lower in SARS-CoV-2 than in SARS-CoV and MERS-CoV. Detection sensitivity is affected | NP expression is lower in SARS-CoV-2 than in SARS-CoV and MERS-CoV. Detection sensitivity is affected |
| Antibody detection assay (Ejazi et al. 2020) | Serum Antibody detection                        | Effective, quick, the specificity of 90.63% and a sensitivity of 88.66%, Detection of False-positive anti-RBD antibody | The sensitivity of the LFA is, however, too low to achieve a highly accurate screening of COVID-19 patients |
| Biosensor Detections (Behera et al. 2020)  | Lateral flow assay (LFA)                        | user-friendly, cheap, and easily mass-produced                     | The sensitivity of the LFA is, however, too low to achieve a highly accurate screening of COVID-19 patients |
|                                            | Electrochemical                                  | Very promising biosensor for highly sensitive point-of-care SARS-CoV-2 detection. Recognized using an antigen–antibody reaction, DNA, RNA, or peptide nucleic acid (PNAs) hybridization or aptamers-based binding High selectivity and sensitivity for the detection target | Not available                                                              |
|                                            | Chip-based nucleic acid detection               | Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable (ASSURED) | Reagent volumes for virus detection in resource-limited settings          |
Fig. 1 The SARS-CoV-2 life cycle inside its host cell; starts when the S protein binding occurs with the ACE2 receptor. After the binding process, the S protein changes enable the fusion of the viral envelope via the cell membrane’s endosomal pathway. Then the RNA is released from the SARS-CoV-2 inside the host cell. The translation of the RNA genome into the viral replicase polyproteins, which produces various viral particles. A sequence of sub-genomic mRNAs are produced by discontinuous transcription and, at last, get translated into viral proteins. These viral proteins and RNA genome are organized in the endoplasmic reticulum and Golgi’s virions, which are further transported through the vesicles, and finally, exocytosis occurs.

(zo-1), PBM found in the last four amino corrosive of the C end. PDZ area can tie to the C-end of the cell connector protein engaged with have cell process that brings about the viral disease (Schoeman and Fielding 2019; Chan et al. 2020; Bianchi et al. 2020). Genetic analysis of the E protein revealed that the protein sequences in SARS-CoV-2 exhibit high identity from Pangolin and Bat isolate. Besides, evidence revealed a distinctive feature of E variants of SARS-CoV-2 in the presence of Arg at position 69, which replaces Asp, Glu, and Gln in SARS-CoV-1 E homologous proteins. Besides, there is a deletion at position 70, which corresponds to Cys or Gly in the other homologous proteins and other existing variations at positions 37, 55 to 56, and at 72 (Bianchi et al. 2020).

Membrane protein (M)

The M protein is considered the most extensive protein in CoV’s structural membrane. The membrane bilayer has the domain of short NH2-terminal in the outer part of the virus. It constitutes the cytoplasmic domain, i.e., the long COOH-terminus in the viral particle’s internal part. It has a vital role in forming the intracellular viral structures without the S protein (Mousavizadeh and Ghasemi 2020). It does not appear to have an enzymatic function, and it is not an ideal target either. Recent evidence revealed structural differences distinctive for SARS-CoV-2M protein that might be linked to the cross-species transmission and viral properties. Several variants were identified in SARS-CoV-2 M protein, including Ser2, Gly3, Val57, Arg89, Ile70, Ser85, and Met175 (Bianchi et al. 2020). Although multiple sequence alignment revealed high structural similarity (~ 98%) between M protein variants in SARS-CoV-2 and counterparts from Pangolin and Bats, the N-terminal position exhibited a variation in position four of the SARS-CoV-2’s M protein, consisting of an insertion of a Ser residue. In contrast, in the homologous proteins, there was a deletion in the RaTG13 Bat and an Asp residue in Bat CoVZC45, CoVZXC21, and Pangolin MP789 isolates.

Nucleocapsid protein (N)

The N protein is primarily involved in binding to the virus’s RNA genome, forming a shell around the nucleic acid. During the viral assembly process, there is a connection between the N-protein and M-protein, assisting the RNA synthesis and folding, which is vital in the viral budding and disturbs the responses like cell cycle and translation in
host cells. Recent evidence revealed that the SARS-CoV-2 N protein manifests high sequence similarity to SARS-CoV-1 (~90.5%) (Zeng et al. 2020). Nevertheless, structural differences that are distinctive for SARS-CoV-2 were reported. Most of the variants identified in the N protein of SARS-CoV-2 were missense mutations (such as 203_204delinsKR, S194L, P13L, and S197L) and synonymous mutations (such as D128D and L139L), and fewer were deletion and insertion mutations (Koyama et al. 2020).

Non-structural proteins (NSPs)

The SARS-CoV genome encodes many proteins, including the replicase gene, a vital element of the genome CoV, encoding for 16 NSPs that constitute two large polypeptides, PP1a PP1ab. Two types of cysteine proteases function on those PPs to activate the NSPs. Chymotrypsin-like cysteine protease cleaves the C-terminal end of these PPs, and the Mpro processes the N-terminal end, which is called papain-like protease (PLpro). PLpro excises the first three cleavage sites in the PPs, while CLpro cleaves the remaining 11 sites, resulting in 16 NSPs release (Prajapat et al. 2020a, b).

Researchers in Gladstone Institute, US, have identified SARS-CoV-2 protein-human protein interactions using affinity purification mass spectroscopy. They discovered 332 SARS-CoV-2 protein-human protein interactions, of which 66 druggable human proteins were identified to be targeted by 69 compounds, of which some are already FDA-approved and in clinical trials (Gordon et al. 2020). According to a recent study, the SARS-CoV-2 genome encodes 14 ORFs. In particular, 5′ Orf1a/Orf1ab encodes polyprotein, which is autoproteolytically processed to 16 NSPs [NSP1-NSP16]. These form the replicase/transcriptase complex (RTC) such as NSP1, the main protease (NSP5), 2′O-methyltransferases (NSP10/NSP16), the primase complex (NSP7/NSP8), papain-like protease (NSP3), a helicase/triphosphatase (NSP13), an exoribonuclease (NSP14), the primary RdRp (NSP12), and an endonuclease (NSP15) (Li 2016). The NSP1 interacts with the DNA replication of the host pathway. The NSP5, NSP8, NSP13 interact with the epigenetic and gene expression regulatory pathway of the host. NSP6, NSP7, NSP10, NSP13, NSP15 interact with vesicle trafficking. NSP8 interacts with RNA processing and regulation of the host pathway. NSP9 interacts with the extracellular matrix and NSP8; NSP13 interacts with the host signaling pathway of the infection’s replication mechanism that makes duplicates of its RNA genome (Chen et al. 2020). The original CoV RdRp exists as mind-boggling with polymerase called NSP12 and some small proteins NSP7 and NSP8. It consists of a shape such as the right hand. The RdRp from SARS-CoV (2002) and SARS-CoV-2 having a similar dynamic site of RNA polymerization and indistinguishable amino corrosive arrangements. Scientists hypothesized that remdesivir drug inhibits the RdRp of SARS-CoV-2, for which the clinical trials have started to test the ability of this drug to the patients infected with SARS-CoV-2. However, it is not clear that how the mutant RdRp works with remdesivir, and a recent study found a potential compound with a higher affinity for both the native and mutant RdRp through virtual screening strategies (Thirumal et al. 2021). The S, M, and E proteins form the envelope and protect the viral particle from external factors (Bianchi et al. 2020; Huang et al. 2020; Thomas 2020). In short, protein structures play a crucial role in drug targets. The S glycoprotein structure of SARS-CoV-2 utilizes the ACE2 receptor of the host for cell entry, followed by other viral proteins exhibiting their role for the viral mechanism inside the host cell.

Evolution and phylogenetic analysis of COVID-19 genomes

A phylogenetic relationship of SARS-CoV-2’s genome was reported in many studies; this method was applied to investigate the phylogenetic relationships among the genomes of CoVs, which investigate the developmental pathways and their ancestral/hereditary genome in the host organism (Forster et al. 2020; Jaimes et al. 2020; Nie et al. 2020). It is mainly applied to investigate human evolution; however, it was applied less in viral evolution (Forster et al. 2020). SARS-CoV-2 is an ancestry of beta-SARS-CoV that belongs to the Coronaviridae family. Unlike SARS-CoV, SARS-CoV-2 possess a distinct evolution and proteolytically-sensitive activation loop, which is believed to be responsible for its high contagiousness and pathogenicity (Jaimes et al. 2020). Recent phylogenetic analyses demonstrated that SARS-CoV-2 was phylogenetically close to the RaTG13, accompanied by GD Pangolin SARSr-CoV, and by GX Pangolin SARSr-CoVs, and now by ZC45 and ZXC21, then by human SARS-CoV, and last by BM48-31 (Tang et al. 2020). As of March 13, 2021, more than 3,12,463 SAR-CoV-2 genomes reported in India, which the clinical trials have started to test the ability of this drug to the patients infected with SARS-CoV-2. However, it is not clear that how the mutant RdRp works with remdesivir, and a recent study found a potential compound with a higher affinity for both the native and mutant RdRp through virtual screening strategies (Thirumal et al. 2021). The S, M, and E proteins form the envelope and protect the viral particle from external factors (Bianchi et al. 2020; Huang et al. 2020; Thomas 2020). In short, protein structures play a crucial role in drug targets. The S glycoprotein structure of SARS-CoV-2 utilizes the ACE2 receptor of the host for cell entry, followed by other viral proteins exhibiting their role for the viral mechanism inside the host cell.
help of Multiple Alignment using Fast Fourier Transform (MAFFT), and Block Mapping and Gathering with Entropy (BMGE) algorithm was applied to compute the appropriate locations for phylogenetic analysis in the query multiple sequence alignment and followed by FastME to compute the pairwise distances and tree (Desper and Gascuel 2002; Junier and Zdobnov 2010; Criscuolo and Gribaldo 2010; Katoh and Standley 2013; Lefort et al. 2015; Lemoine et al. 2019). For further visualization of the output tree, we used the Interactive Tree Of Life (iTOl) (Letunic and Bork 2019) (Fig. 2). The SARS-CoV-2 genomes from Indian isolates exhibited a common PANGOLIN lineage, which is highly transmissible (B.1/B.1.1/B.1.36) with mutation (D614G); whereas, the B.6 lineage reported as a second common and least transmissible owing to the absence of mutation in S protein (Jacob et al. 2020; Banu et al. 2020; Koyama et al. 2020). Intriguingly, the Gujarat dominant lineage B.1.36 contains one-three S protein mutations that would lead to higher infection rates.

Fig. 2 Analysis of phylogeny relationship between the Indian SARS-CoV-2 genomes of Coronaviridae from GISAID (https://www.gisaid.org/epituu-applications/hcov-19-genomic-epidemiology/). Nearly 775 high-quality genomes were retrieved and conducted the phylogenetic analysis with NGPhylogeny (https://ngphylogeny.fr). An interactive view of phylogeny was plotted using Interactive Tree Of Life (iTOl) (https://itol.embl.de/). The genome names (nodes) are displayed in red font, branch length from the root was provided in red font for each circle (blue and gray) with designated values. The internal node symbols were depicted in black dots (Display mode: Circular; Gap Penalty = −1.53, +0.00, −0.12; Tree scale: 0.0001)
Therapeutic management of COVID-19

COVID-19 treatment requires clinical care, including aid in oxygen, fluid therapy, and support for other internal organs affected. Current potential therapeutics used against COVID-19 include antibodies, anti-virals, cell-based compounds, RNA-based compounds, anti-inflammatory agents, antimalarial agents, and protein-based antibiotics (Lu 2020). Figure 3 Summarizes current pre-clinical and clinical treatments available to treat COVID-19 (Milken Institute 2020). Table 3 includes a comprehensive description of the clinical evidence for the therapies being studied and Supplementary Table 2. Evidence showed that outpatients could be benefited from acquiring monoclonal antibodies against SARS-CoV-2 early. Bamlanivimab and casirivimab plus imdevimab monoclonal antibodies as anti-SARS-CoV-2 are provided via EUA for patients at high risk of disease progression.

Remdesivir (Veklury), an anti-viral agent, is the only FDA-approved drug for the COVID-19 treatment. The course of therapy of remdesivir was found to be effectively tolerated but is not efficacious in critical COVID-19 cases (Ko et al. 2020; Wang et al. 2020b, c). Other anti-viral agents, including hydroxychloroquine and chloroquine, umifenovir, lopinavir-ritonavir, favipiravir, and oseltamivir, are currently being analyzed in vivo and in vitro (Table 3, Supplementary Table 2) (Wu et al. 2020; Biorender 2020). Oseltamivir joined with direct anti-infection utilization, has been utilized to treat patients with SARS-CoV-2 (Huang et al. 2020a). The adequacy and safety measures of lopinavir-ritonavir and interferon-α 2b in COVID-19 patients are still being investigated (Habibzadeh and Stoneman 2020). In vitro evidence using the antiparasitic drug, ivermectin has effectively worked as a potential therapeutic against SARS-CoV-2 in 48 h. However, the safety and applicability in humans remain to be investigated (Caly et al. 2020). In hospitalized patients who need supplemental oxygen, corticosteroids, including dexamethasone, have been shown to enhance longevity, with the overall benefit seen in patients requiring mechanical ventilation. Hence, dexamethasone usage in this condition is highly recommended (Horby et al. 2020; Jeronimo et al. 2020; Angus et al. 2020; Tomazini et al. 2020).

Why protease of COVID-19 be the best drug target?

The crystal structures are always more reliable than computational models (Forrest et al. 2006). The crystal structure of the Mpro (PDB ID- 6LU7) could be the potential drug target with this aspect. It was not limited to this availability, but protease was essential in replicating the virus (Patick and Potts 1998). Replication occurs within the cytoplasm of the host cells that are infected. The coronaviruses’ single-stranded RNA genome is released in the cytoplasm, where it is translated to form a replicase complex, which is then processed proteolytically into NSPs by viral proteases (van Boheemen et al. 2012; Kilianski et al. 2013). This makes it an excellent choice to inhibit the replicating virus and henceforth the viral assembly and its release. Coronavirus

![Fig. 3](image-url) COVID-19 therapeutic candidates in both clinical and preclinical development. Diverse categories of pre-clinical and clinical research COVID-19 therapeutic candidates are currently in development— source: COVID-19 vaccine and treatments tracker, Milken Institute (Milken Institute 2020)
| Drug Candidate | Organization | Technology | Stage          |
|----------------|--------------|------------|----------------|
| Valsartan      | Radboud Universit, National University of Ireland, Galway, Ireland | Other | Phase IV  |
| Ebastine<sup>a</sup> | Mianyang Central Hospital | Antivirals | Phase IV  |
| Danoprevir<sup>a</sup> | Asclelis Pharmaceuticals Co., Ltd., The Ninth Hospital of Nanchang | Antivirals | Phase IV  |
| Bivalirudin     | Hamad Medical Corporation | Other | Phase IV  |
| Somatotropin   | ClinAmygate   | Dormant/Discontinued | Phase IV |
| Darunavir<sup>a</sup> | Multiple organizations | Antivirals | Phase III/IV|
| Novafenon      | Multiple organizations | Other | Phase III/IV|
| Ravulizumab    | Multiple organizations | Antibodies | Phase III/IV|
| Carrimycin     | Multiple organizations | Other | Phase III/IV|
| Nintedanib     | Multiple organizations | Other | Phase III/IV|
| Telmisartan    | Multiple organizations | Other | Phase II/III/IV|
| Tocilizumab<sup>b</sup> | Multiple organizations | Antibodies | Phase II/III/IV|
| Corticosteroid Therapy<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Tissue plasminogen activator | Multiple organizations | Other | Phase II/III/IV|
| Granulocyte–Macrophage Colony-Stimulating Factor | Multiple organizations | Other | Phase II/III/IV|
| Anakinra<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Nitazoxanide<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Eicosapentaenoic Acid Free Fatty Acid | Multiple organizations | Other | Phase II/III/IV|
| Rivaroxaban<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Interferon beta-1a<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Baricitinib<sup>b</sup> | Multiple organizations | Other | Phase II/III/IV|
| Candesartan<sup>b</sup> | Multiple organizations | Other | Phase II/III/IV|
| Doxycycline<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Sofosbuvir<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Ledipasvir<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| (Hydroxy)Chloroquine<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Lopinavir<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Favipiravir<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Sarilumab<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Convalescent plasma | Multiple organizations | Other | Phase II/III/IV|
| Intravenous Immunoglobulin | Multiple organizations | Other | Phase II/III/IV|
| Ritonavir<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Camostat Mesylate<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Interferon alpha | Multiple organizations | Other | Phase II/III/IV|
| Losartan<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Ivermectin<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Azithromycin<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Low Molecular Weight Heparin<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Bamlanivimab | Multiple organizations | Antibodies | Phase II/III/IV|
| N-acetylcysteine | Multiple organizations | Other | Phase II/III/IV|
| Povidone-Iodine | Multiple organizations | Other | Phase II/III/IV|
| Dexamethasone<sup>a</sup> | Multiple organizations | Other | Phase II/III/IV|
| Olitilumab | GlaxoSmithKline | Antibodies | Phase III |
| ASC09<sup>a</sup> | Multiple organizations | Other | Phase III |
| Azvudine | Multiple organizations | Other | Phase III |
| Remestemcel-L | Mesoblast, Inc, Icahn School of Medicine at Mount Sinai | Cell-based therapies | Phase III |
| Drug Candidate       | Organization                                      | Technology  | Stage    |
|---------------------|---------------------------------------------------|-------------|----------|
| CD24Fc              | OncoImmune, Inc                                   | Other       | Phase III|
| INOpulse            | Bellerophon                                      | Device      | Phase III|
| Cobicistat\(^a\)    | Multiple Organizations                           | Antivirals  | Phase III|
| Tradipitant         | Vanda Pharmaceuticals                             | Other       | Phase III|
| Brensocatib         | Insmed Inc., University of Dundee                 | Other       | Phase III|
| Pacritinib           | CTI Biopharma                                    | Other       | Phase III|
| Almitrine           | Multiple organizations                            | Other       | Phase III|
| Levilimab           | Biocad                                            | Antibodies  | Phase III|
| Prasugrel           | Azienda Ospedaliera Universitaria Integrata       | Other       | Phase III|
| NK-1R antagonist    | University of Lahore, Bahria International Hospital | Other       | Phase III|
| Rosuvastatin\(^3\)  | Yale University                                   | Other       | Phase III|
| XC221               | RSV Therapeutics LLC                              | Antivirals  | Phase III|
| Broncho-Vaxom       | Multiple organizations                            | Other       | Phase III|
| Bucillamine         | Revive Therapeutics, Ltd                          | Other       | Phase III|
| Losmapimod          | Fulcrum Therapeutics                              | Other       | Phase III|
| Edoxaban\(^a\)      | University Hospital Inselspital, Berne, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Other       | Phase III|
| Brexanolone         | Sage Therapeutics                                 | Other       | Phase III|
| NA-831\(^a\)        | NeuroActiva, Inc., Biomed Industries, Inc         | Other       | Phase III|
| Nicotine            | Assistance Publique—Hôpitaux de Paris             | Other       | Phase III|
| Lidocaine           | Multiple Organizations                            | Other       | Phase III|
| Fenofibrate         | Hebrew University of Jerusalem, Barzilai Medical Center | Other       | Phase III|
| Fluvoxamine         | Washington University School of Medicine, Covid-19 Early Treatment Fund | Other       | Phase II/III|
| Tranexamic Acid     | University of Alabama at Birmingham               | Other       | Phase II/III|
| Lenzilumab          | Multiple organizations                            | Antibodies  | Phase II/III|
| Bevacizumab         | Multiple organizations                            | Antibodies  | Phase II/III|
| Situximab\(^4\)     | Multiple organizations                            | Antibodies  | Phase II/III|
| Eculizumab          | Multiple organizations                            | Antibodies  | Phase II/III|
| Canakinumab         | Multiple organizations                            | Antibodies  | Phase II/III|
| Emapalumab          | Swedish Orphan Biovitrum                          | Antibodies  | Phase II/III|
| IFX-1               | Multiple organizations                            | Antibodies  | Phase II/III|
| Truvada\(^a\)       | Multiple organizations                            | Antibodies  | Phase II/III|
| VIR-7831            | Vir Biotechnology, Inc., GlaxoSmithKline          | Antibodies  | Phase II/III|
| Multipotent Adult Progenitor Cells | Athersys, Inc                        | Cell-based therapies | Phase II/III|
| Ifenprodil          | Algenron Pharmaceuticals, Novotech                | Other       | Phase II/III|
| Nafamostat          | Multiple organizations                            | Other       | Phase II/III|
| Colchicine\(^a\)    | Multiple organizations                            | Other       | Phase II/III|
| Selinexor           | Karyopharm therapeutics, Peter MacCallum Cancer Centre, Australia | Other       | Phase II/III|
| Vazegepant          | Biohaven Pharmaceuticals, Inc                     | Other       | Phase II/III|
| Dapagliflozin\(^a\)| Multiple organizations                            | Other       | Phase II/III|
| Imatinib\(^b\)      | Multiple organizations                            | Other       | Phase II/III|
| DAS181              | Multiple organizations                            | Antivirals  | Phase II/III|
| Dipyridamole        | Multiple organizations                            | Other       | Phase II/III|
| ABX464              | Abivax S.A                                        | Other       | Phase II/III|
| Dociparastat sodium | Chimerix                                          | Other       | Phase II/III|
| Drug Candidate           | Organization                                                                 | Technology  | Stage       |
|-------------------------|------------------------------------------------------------------------------|-------------|-------------|
| EDP1815                 | Cambridge University Hospitals NHS Foundation Trust, Evelo Biosciences, Inc | Other       | Phase II/III|
| Mavrilimumab            | Multiple organizations                                                       | Antibodies  | Phase II/III|
| Levamisolea             | Multiple organizations                                                       | Other       | Phase II/III|
| Secukinumab             | Assistance Publique—Hôpitaux de Paris, Lomonosov Moscow State University Medical Research and Educational Center | Antibodies  | Phase II/III|
| RTB101                  | Restorbio Inc., National Institute on Aging                                  | Other       | Phase II/III|
| Tacrolimus              | Hospital Universitari de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge | Other       | Phase II/III|
| Hyperbaric chamber      | Multiple organizations                                                       | Device      | Phase II/III|
| Opaganib                | RedHill Biopharma Limited, Shaare Zedek Medical Center                      | Other       | Phase II/III|
| Lactoferrin             | Multiple organizations                                                       | Other       | Phase II/III|
| Clazakizumab            | Multiple organizations                                                       | Antibodies  | Phase II/III|
| Ambrisentan             | Cambridge University Hospitals NHS Foundation Trust                         | Other       | Phase II/III|
| PTC299                  | PTC therapeutics                                                             | Other       | Phase II/III|
| Daclatasvir             | Multiple organizations                                                       | Antivirals  | Phase II/III|
| BDB-001                 | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd | Other       | Phase II/III|
| Olokizumab              | Multiple organizations                                                       | Antibodies  | Phase II/III|
| NA-831                  | NeuroActiva, Inc                                                             | Other       | Phase II/III|
| Atazanavir              | Multiple organizations                                                       | Antivirals  | Phase II/III|
| RPH-104                 | Multiple organizations                                                       | Other       | Phase II/III|
| RESP301                 | Thirty respiratory limited                                                   | Other       | Phase II/III|
| Atorvastatin            | Multiple organizations                                                       | Other       | Phase II/III|
| Acetylsalicylic acid    | Multiple organizations                                                       | Other       | Phase II/III|
| BIO101                  | Biophytis                                                                    | Other       | Phase II/III|
| TD139                   | University of Edinburgh, University of Oxford                               | Other       | Phase II/III|
| Melatonin               | Multiple Organizations                                                       | Other       | Phase II/III|
| Itolizumab              | Biocon Limited, Equillum                                                     | Antibodies  | Phase II/III|
| Apremilast              | QuantumLeap Healthcare Collaborative, Amgen                                   | Other       | Phase II/III|
| Bardoxolone methyl      | NYU Langone Health, Reata Pharmaceuticals, Inc                              | Other       | Phase II/III|
| INM005                  | ImmunoVA S.A.                                                                | Antibodies  | Phase II/III|
| Bicalutamide            | University of Florida, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Other       | Phase II/III|
| Metformin               | Multiple organizations                                                       | Other       | Phase II/III|
| IMU-838                 | Multiple organizations                                                       | Other       | Phase II/III|
| Triazavirin             | Multiple organizations                                                       | Antivirals  | Phase II/III|
| Furosemide              | Queen’s University, University Health Network, Toronto                       | Other       | Phase II/III|
| Recombinant Nematode Anticoagulant Protein c2 | ARCA Biopharma, Inc., Colorado Prevention Center                                      | Other       | Phase II/III|
| Remdesivir              | Multiple Organizations                                                       | Antivirals  | Phase I/II/III|
| Thymosin                | Multiple Organizations                                                       | Other       | Phase I/II/III|
| Meplazumab              | Tang-Du Hospital, Jiangsu Pacific Meinouke Bio Pharmaceutical Co Ltd         | Antibodies  | Phase I/II/III|
| Ribavirin               | Multiple organizations                                                       | Other       | Phase I/II/III|
| Ruxolitinib             | Multiple organizations                                                       | Other       | Phase I/II/III|
| Nitric Oxide            | Multiple organizations                                                       | Other       | Phase I/II/III|

*Table 3 (continued)*
proteases are known to be multifunctional. Studies have shown that coronavirus has the DUB and deISGylyating to evade innate immune systems (Komander et al. 2009; Jeon et al. 2010). Some of the mechanisms that the virus adapts to evade the immune system include (1) inhibition of the poly I: C by the protease leading to the activation of the TRIF and further the NF-κB signaling. (2) Downregulation of the IFR3 phosphorylation, thereby preventing its dimerization, results in the signal cascade’s termination. (3) Protease is also known to repress the IFN signalling. (4) Protease can stabilize the Ik Bα, in turn, inactivating the NF-κB, a transcription factor for the activation of the inflammatory cytokines. (5) Activation of NF-κB by TNFα is blocked by protease (Devaraj et al. 2007; Frieman et al. 2009; Clementz et al. 2010). Protease inhibitors can bind to the protease, thereby activating the signaling pathway and release of pro-inflammatory cytokines, and hence are an excellent choice for the anti-viral agent.

The main protease of SARS-CoV-2, referred to as the 3C-like protease (3CLpro), was identified as a target for post-infection drugs in March 2020. 3CLpro enzyme plays a crucial role in the replication and life cycle of the virus. The human immunodeficiency viruses (HIV) protease inhibitors lopinavir and ritonavir have evidence of activity against the coronaviruses, including SARS-CoV and MERS-CoV (Li and Clercq 2020; Kupferschmidt et al. 2020). They have recently been proposed as a potential combination therapy against COVID-19 (Table 3 and Supplementary Table 2) (Kupferschmidt et al. 2020; Mullard 2020; Mishra et al. 2020). Nevertheless, a recent preliminary study in China of lopinavir/ritonavir combination therapy found no effect in people hospitalized for COVID-19 (Cao et al. 2020). Efforts are currently directed towards identifying novel protease inhibitors that target the protease 3CLpro, such as GC376 (Supplementary Table 2) (Ramajayam et al. 2011; Morse et al. 2020; Liu et al. 2020). Other protease inhibitors include bromhexine hydrochloride (Table 3), which reduced patients’ mortality rate with COVID-19 (Ansarin et al. 2020). Besides, it can reduce infection, which could be used to treat COVID-19 as a prophylactic treatment (Ansari et al. 2020). Oral camostat mesylate is another prophylactic option for treatment COVID-19 treatment (Table 3 and Supplementary Table 2). Research findings have shown that it prevents the SARS-CoV-2 entry into the hosts, indicating its potential effectiveness in treatment (Hoffmann et al. 2020).

### Table 3 (continued)

| Drug Candidate | Organization | Technology | Stage |
|----------------|--------------|------------|-------|
| Aviptadil      | Multiple organizations | Other | Phase I/II/III |
| Niclosamide<sup>a</sup> | Multiple organizations | Other | Phase I/II/III |
| Interferon beta-1b<sup>b</sup> | Multiple organizations | Other | Phase I/II/III |
| Molnupiravir   | Multiple organizations | Antivirals | Phase I/II/III |
| Angiotensin 1–7 | Multiple organizations | Other | Phase I/II/III |
| DNases         | Multiple organizations | Other | Phase I/II/III |
| REGN-COV2      | Regeneron Pharmaceuticals | Antibodies | Phase I/II/III |
| SCTA01         | Sinocelltech Ltd | Antibodies | Phase I/II/III |
| Fostamatinib   | Multiple organizations | Other | Phase I/II/III |
| CT-P59         | Celltrion | Antibodies | Phase I/II/III |
| Umifenovir<sup>a</sup> | Multiple organizations | Antivirals | Phase I/IV |
| Oseltamivir<sup>a</sup> | Multiple organizations | Antivirals | Phase I/III/IV |
| Famotidine     | Multiple organizations | Other | Phase I/II/III |
| Cyclosporine   | Multiple organizations | Other | Phase I/II/III |
| TY027          | Tychan Pte Ltd | Antibodies | Phase I/III |
| Bromhexine<sup>a</sup> | Multiple organizations | Other | Phase I/II/III |
| Therapeutic Plasma Exchange | Multiple organizations | Other | Phase II/IV |
| Chlorhexidine  | NYU Langone Health, Ohio State University | Other | Phase II/IV |
| AZD7442        | Multiple organizations | Antibodies | Phase I/III |

<sup>a</sup>May be used in combination with other therapeutics. Clinical trials mentioned contain this included drug in the regimen
<sup>b</sup>FDA approved for COVID−19 treatment. This Table was last updated on December 14, 2020. Treatments that have not reached phase III clinical trials are not shown in this Table—source BioRender Vaccine and therapeutics Tracker (Biorender 2020)
Role of drug repurposing in the field of drug discovery

The global pharmaceutical industries face many challenges, including attenuation of the drugs and higher cost due to an increased number of years to bring a drug to the market and changes in the regulatory requirements (Pammolli et al. 2011; Waring et al. 2015). Drug repurposing is also known as the reprofiling or repositioning of drugs. It is an approach to identify novel uses of the already established or approved drug to treat a new disease other than the first indication (Ashburn and Thor 2004). In the early days, drug repurposing has been mostly expedient; once a drug is discovered, and the drug shows its effect on different sites other than the targeted site, it was taken for commercial manipulation (Pushpakom et al. 2019). The advantages of the drug repurposing approaches are: (1) the risk of drug failure is shallow because the drug used for repositioning was already proven to be reasonably safe enough in pre-clinical, experimental models and also in the clinical trials; (2) the time entailed for the development of a drug can also be reduced because of the pre-clinical testing and safety assessment, which has already been completed; and (3) only less fund is required for the development of a repurposing drug, depending on the stage and also the procedure of development (Breckenridge and Jacob 2019). The regulatory and phase III trial cost may remain the same, but the cost of phase I and II trial can be reduced or saved.

Drug repurposing approach to treat COVID-19

Researchers have started testing existing anti-viral drugs that are widely used to treat HIV in hopes that they might be able to fight the COVID-19 (Supplementary Table 2). A randomized controlled trial of the combination of ritonavir and lopinavir, an anti-HIV drug, is also being tested (Huang et al. 2020a). The trials with other identified anti-viral drugs against other viral diseases like Ebola may benefit from another anti-viral testing. The use of marketed drugs whose safety profile is known could be used as adjuncts to monotherapy. Combinatorial therapies with cyclosporin, ribavirin, lopinavir-ritonavir, interferon beta-1b, remdesivir, monoclonal antibodies can be tested to prevent or curb the infection (Beigel et al. 2019; Singh et al. 2020). The replication of coronavirus and release in cytoplasm forms a replicate complex that is then processed proteolytically into NSPs by viral proteases (van Boheemen et al. 2012; Kilianski et al. 2013). This makes it an excellent choice to inhibit replicating the virus and henceforth the viral assembly and its release. Since no specific drug or vaccine is identified and approved when we wrote the manuscript for COVID-19 treatment, the best medication to be followed is a repurposing of anti-viral drugs. There must be an imminent need to control the widespread SARS-CoV-2 transmission repurposing as an effective treatment to prevent the rapid spread.

Current COVID-19 vaccine candidates

Several promising candidate vaccines have been developed by researchers, which have shown efficacy in phase trials II and III; 166 candidate vaccines are in pre-clinical evaluation, and 56 vaccines are in the clinical evaluation as of December 16, 2020. Figure 4 Summarizes candidate COVID-19 vaccines in pre-clinical and clinical trials (WHO 2020b). A detailed description of the vaccines can be found in Table 4 and Supplementary Table 3. Four candidate vaccines have cleared phase III trials (Moderna’s mRNA-1273, Pfizer/BioNTech’s BNT162b2, Gamaleya’s Sputnik V vaccine University-Oxford & AstraZeneca’s AZD1222). On December 11, 2020, and December 18, 2020, the U.S. Food and Drug Administration (FDA) issued emergency use authorization (EUA) for the Pfizer-BioNTech and Moderna COVID-19 Vaccines, respectively (Table 4, Supplementary Table 3).

Future outlook

The on-going outbreak of COVID-19 induced by the novel SARS-CoV-2 has put the world on red caution as it continues spreading and causing more fatalities. Exploration endeavors are being completed to diminish the SARS-CoV-2 and its variants from spreading. Discovering medications is commonly known as a long process that takes time. Different computer-aided drug designs (CADD) are assessed as promising strategies among all these structure-based medication plans. Ligand-based medication configuration approaches are known as valuable and ground-breaking procedures in tranquilize revelation advancement. These strategies can be
applied with atomic docking to virtual screening for potential lead identification and enhancement. Currently, computational instruments are utilized in pharmaceutical ventures and examination regions to improve the medication disclosure and advancement pipeline's viability and adequacy. On the other hand, understanding the host-virus relationships and transcriptomic profiles of COVID-19 patients will prioritize gene targets that will lead to developing therapeutic drugs (Alsamman and Zayed 2020).

Conclusion

The COVID-19 outbreak has put health systems on a red alert as it quickly spreads globally. Old individuals and patients with chronic diseases are at high risk of developing severe symptoms and potential death from COVID-19. Researchers worldwide are struggling and trying hard to find effective treatments for COVID-19. In addition, drug repurposing can be achieved using existing FDA-approved anti-viral drugs for COVID-19. Since the described drugs are FDA-approved, their efficacy in treating the infection is expected to be less toxic to patients. This could lower the disease’s severity in elderly patients and protect lives. The Mpro, S glycoproteins, PLpro, RdRp, and 3CLpro of COVID-19 can be targeted using novel inhibitors or existing drug inhibitors to disable its infection ability altogether. Furthermore, the nanoemulsions, nanospheres, nanoparticles, nano-gels, liposomes, and nanosuspensions can be used for anti-viral drug delivery. This also defines and proposes an approach to address existing key challenges, thus directing scientists worldwide to perhaps refining the delivery of nano-based drugs as a strategy to combat virus outbreaks successfully. Further understanding of the molecular pathology of COVID-19 is expected to help in the discovery and development of drugs against COVID-19.
| Developers and Institutions | Vaccine Platform | Type of Candidate Vaccine | Number of Doses | Dosing Schedule | Route of Administration | Phase |
|-----------------------------|------------------|--------------------------|----------------|----------------|------------------------|-------|
| Sinovac Research and Development Co., Ltd | IV | SARS-CoV-2 vaccine (inactivated) | 2 | Day 0 + 14 | IM | Phase III |
| Sinopharm + Wuhan Institute of Biological Products | IV | Inactivated SARS-CoV-2 vaccine (Vero cell) | 2 | Day 0 + 21 | IM | Phase III |
| Sinopharm + Beijing Institute of Biological Products | IV | Inactivated SARS-CoV-2 vaccine (Vero cell) | 2 | Day 0 + 21 | IM | Phase III |
| AstraZeneca + University of Oxford | VVnr | ChAdOx1-S—(AZD1222) (Covishield) | 1–2 | Day 0 + 28 | IM | Phase III |
| Gamaleya Research Institute; Health Ministry of the Russian Federation | VVnr | Gam-COVID-Vac Adeno-based (rAd26-S + rAd5-S) | 2 | Day 0 + 21 | IM | Phase III |
| Janssen Pharmaceutica | VVnr | Ad26.COV2.S | 1–2 | Day 0 or Day 0 + 56 | IM | Phase III |
| Novavax | VVnr | Recombinant novel coronavirus vaccine | 2 | Day 0 + 21 | IM | Phase III |
| Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | RNA | mRNA -1273 | 2 | Day 0 + 28 | IM | Phase III |
| BioNTech + Fosun Pharma; Jiangsu Provincial Center for Disease Prevention and Control+ Pfizer | RNA | BNT162 (3 LNP-mRNAs) | 2 | Day 0 + 28 | IM | Phase II/III |
| Anhui Zhifei Longcom Biopharmaceutical+ Institute of Microbiology, Chinese Academy of Sciences | PS | SARS-CoV-2 vaccine (CHO Cell) | 2–3 | Day 0 + 28 or Day 0 + 28 + 56 | IM | Phase III |
| Curevac AG | RNA | CVnCoV Vaccine | 2 | Day 0 + 28 | IM | Phase II |
| Institute of Medical Biology + Chinese Academy of Medical Sciences | IV | SARS-CoV-2 vaccine | 2 | Day 0 + 28 | IM | Phase I/II |
| Research Institute for Biological Safety Problems, Rep of Kazakhstan | IV | QazCovid-in®—COVID-19 inactivated vaccine | 2 | Day 0 + 21 | IM | Phase I/II |
| Inovio Pharmaceuticals + International Vaccine Institute | DNA | INO-4800+ electroporation | 2 | Day 0 + 28 | ID | Phase II/III |
| AnGes + Takara Bio + Osaka University | DNA | AG0301-COVID19 | 2 | Day 0 + 14 | IM | Phase I/II |
| Cadila Healthcare Ltd | DNA | nCoV vaccine | 3 | Day 0 + 28 + 56 | ID | Phase I/II |
| Genexine Consortium | DNA | GX-19 | 2 | Day 0 + 28 | IM | Phase I/II |
| Bharat Biotech International Limited | IV | Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) | 2 | Day 0 + 14 | IM | Phase III |
| Kentucky Bioprocessing Inc | PS | KBP-COVID-19 (RBD-based) | 2 | Day 0 + 21 | IM | Phase I/II |
| Sanofi Pasteur + GSK | PS | SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S protein (baculovirus production) | 2 | Day 0 + 21 | IM | Phase I/II |
| Arcturus Therapeutics | RNA | ARCT-021 | ND | ND | IM | Phase I/II |
| Developers | Vaccine platform acronym | Type of candidate vaccine | Number of doses | Dosing schedule | Route of administration | Phase |
|------------|--------------------------|---------------------------|-----------------|----------------|-------------------------|-------|
| Serum Institute of India + Accelagen Pty Ltd | VLP | RBD SARS-CoV-2 HBsAg VLP vaccine | 2 | Day 0+28 | IM | Phase I/II |
| Shenzhen Kangtai Biological Products Co., Ltd | IV | Inactivated SARS-CoV-2 vaccine (Vero cell) | 1, 2 or 3 | ND | IM | Phase I/II |
| ReiThera + Leukocare + Univercells | VVnr | GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) | 1 | Day 0 | IM | Phase I |
| Vaxart | VVnr | VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform | 2 | Day 0+28 | Oral | Phase I |
| University of Munich (Ludwig-Maximilians) | VVnr | MVA-SARS-CoV-2-S | 2 | Day 0+28 | IM | Phase I |
| Clover Biopharmaceuticals Inc./GSK/Dynavax | PS | SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native like Trimeric subunit Spike Protein vaccine) | 2 | Day 0+21 | IM | Phase I |
| Vaxine Pty Ltd. + Medytox | PS | COVID19 vaccine | 1 | Day 0 | IM | Phase I |
| CSL Ltd. + Seqirus + University of Queensland | PS | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine | 1 | Day 0+28 | IM | Phase I |
| Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID) | PS | MVC-COV1901 (S-2P protein + CpG 1018) | 2 | Day 0+28 | IM | Phase I |
| Instituto Finlay de Vacunas | PS | FINLAY-FR anti-SARS-CoV-2 Vaccine (RBD+adjuvant) | 2 | Day 0+28 | IM | Phase I/II |
| Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | PS | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | 2 | Day 0+21 | IM | Phase I/II |
| West China Hospital + Sichuan University | PS | RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) | 2 | Day 0+28 | IM | Phase II |
| University Hospital Tuebingen | PS | IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) | 1 | Day 0 | SC | Phase I |
| COVAXX + United Biomedical Inc | PS | UB-612 (Multitope peptide based S1-RBD-protein based vaccine) | 2 | Day 0+28 | IM | Phase I |
| Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of Pittsburgh | VVr | V591-001—Measles-vector based (TMV-v38) | 1–2 | Day 0+28 | IM | Phase I/II |
| Jiangsu Provincial Center for Disease Prevention and Control | VVr | DeINSi-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD) | 1 | Day 0 | IN | Phase II |
| Imperial College London | RNA | LNP-nCoVsaRNA | 2 | ND | IM | Phase I |
| Shulan (Hangzhou) Hospital + Center for disease control and Prevention of Guangxi Zhuang Autonomous Region | RNA | SARS-CoV-2 mRNA vaccine | 2 | Day 0+14 or Day 0+28 | IM | Phase I |
Table 4 (continued)

| Developers | Vaccine platform acronym | Type of candidate vaccine | Number of doses | Dosing schedule | Route of administration | Phase |
|------------|--------------------------|---------------------------|-----------------|-----------------|-------------------------|-------|
| Medicago Inc | VLP | Coronavirus-Like Particle COVID-19 (CoVLP) | 2 | Day 0+21 | IM | Phase II/III |
| Shenzhen Geno-Immune Medical Institute | VVr + APC | Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune-modulatory genes and the viral minigenes to the artificial antigen-presenting cells (aAPCs) | 3 | Day 0+14+28 | SC | Phase I |
| Shenzhen Geno-Immune Medical Institute | VVnr + APC | LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune-modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens | 1 | Day 0 | SC & IV | Phase I/II |
| Barbara Carlson, University of Oklahoma | PS | (SHINGRIX) Zoster Vaccine Recombinant, Adjuvanted | 2 | Day 0+60 | IM | Phase I |
| Adimmune Corporation | PS | AdimrSC-2f (recombinant RBD ± Aluminium) | ND | ND | ND | Phase I |
| Entos Pharmaceuticals Inc | DNA | Covigenix VAX-001 | 2 | Day 0+14 | IM | Phase I |
| Providence Health & Services | DNA | CORVax | 2 | Day 0+14 | ID | Phase I |
| Chulalongkorn University | RNA | ChulaCov19 mRNA vaccine | 2 | Day 0+21 | IM | Phase I |
| Symvivo Corporation | DNA | bacTRL-Spike | 1 | Day 0 | Oral | Phase I |
| ImmunityBio, Inc | VVnr | hAd5-S-Fusion + N-ETSD vaccine | 1 | Day 0 | Oral | Phase I |
| City of Hope Medical Center + National Cancer Institute | VVnr | COH04S1 (MVA-SARS-2-S) | 1–2 | Day 0+28 | IM | Phase I |
| Israel Institute for Biological Research | VVr | rSV-SARS-CoV-2-S Vaccine | 1 | Day 0 | IM | Phase I |
| Aivita Biomedical, Inc | VVr + APC | Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF | 1 | Day 0 | IM | Phase I/II |
| Codagenix/Serum Institute of India | LAV | COVI-VAC | 1–2 | Day 0 or Day 0+28 | IN | Phase I |
| Center for Genetic Engineering and Biotechnology (CIGB) | PS | CIGB-669 (RBD + AgnHB) | 3 | Day 0+14+28 or Day 0+28+56 | IN | Phase I/II |
| Center for Genetic Engineering and Biotechnology (CIGB) | PS | CIGB-66 (RBD + aluminium hydroxide) | 3 | Day 0+14+28 or Day 0+28+56 | IM | Phase I/II |

ND: No data, LAV: Live attenuated virus, IV: Inactivated virus, PS: Protein subunit, RNA: RNA based vaccine, DNA: DNA based vaccine, VLP: Virus like particle, VVr: Viral vector (Replicating), VVnr: Viral vector (Non−replicating), APC: Antigen presenting cell, IM: Intramuscular, ID: Intradermal, SC: Subcutaneous, IV: Intravenous, IN: Injectable

Source: World Health Organization (WHO), The COVID−19 Candidate Vaccine Landscape (WHO 2020b)
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13205-021-02749-0.

Acknowledgements Mr. Ud haya Kumar S., one of the authors, gratefully acknowledges the Indian Council of Medical Research (ICMR), India, for providing him a Senior Research Fellowship [ISRM/11(93)/2019]. The authors would like to take this opportunity to thank the management of VIT for providing the necessary facilities and encouragement to carry out this work.

Author contributions SUK, CGPD, and HZ were involved in the design of the review. SUK, DTK, NMP, NJ, SRN, PK, MR, SY, HZ, and CGPD were involved in drafting the manuscript. CGPD, HZ, and MR supervised the entire study design, the acquisition, and the drafting of the manuscript. The manuscript was reviewed and approved by all the authors.

Funding Not applicable for the present study.

Declarations

Conflict of interest The authors have declared that no conflicts of interest exist.

References

Ai J-W, Zhang Y, Zhang H-C et al (2020) Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned. Emerg Microbes Infect 9:597–600. https://doi.org/10.1080/22221751.2020.1738905

Alsamman AM, Zayed H (2020) The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1. PLoS ONE. https://doi.org/10.1371/journal.pone.0243270

Angus DC, Derde L, Al-Beidh F et al (2020) Effect of hydrocortisone and membrane proteins: Structural differences linked to virus characteristics? In: BioMed Research International. https://doi.org/10.1007/s13205-021-02749-0

Beigel JH, Nam HH, Adams PL et al (2019) Advances in respiratory virus therapeutics—a meeting report from the 6th isivr Antiviral Group conference. Antiviral Res 167:45–67. https://doi.org/10.1016/j.antiviral.2019.04.006

Bianchi M, Benvenuto D, Giovannetti M, et al (2020) Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? In: BioMed Research International. https://doi.org/10.1007/s13205-021-02749-0

Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 382:1787–1799. https://doi.org/10.1056/NEJMoa2001282

Cascella M, Rajnik M, Cuomo A et al (2020) Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls. StatPearls Publishing, Treasure Island (FL)

Chan JF-W, Kok K-H, Zhu Z et al (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9:221–236. https://doi.org/10.1080/22221751.2020.1719902

Chen Y, Guo D (2016) Molecular mechanisms of coronavirus RNA capping and methylation. Virol Sin 31:3–11. https://doi.org/10.1002/jmv.25681

Chen Y, Liu Q, Guo D (2020) Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418–423. https://doi.org/10.1002/jmv.25681

Clement MA, Chen Z, Banach BS et al (2010) Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol 84:4619–4629. https://doi.org/10.1128/JVI.02406-09

Coutard B, Valle C, de Lamballerie X et al (2020) The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 176:104742. https://doi.org/10.1016/j.antiviral.2020.104742

Crisculo A, Gribaldo S (2010) BMGE (Block Mapping and Gather -ing) for constructing evolutionary trees from protein sequences. Bioinformatics 26:1611–1617. https://doi.org/10.1093/bioinformatics/btq206

Devaraj SG, Wang N, Chen Z et al (2007) Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem 282:32208–32221. https://doi.org/10.1074/jbc.M704870200

Dong X, Cao Y, Lu X et al (2020) Eleven faces of coronavirus disease 2019. Allergy 75:1699–1709. https://doi.org/10.1111/all.14289

Ejazi SA, Ghosh S, Ali N (2020) Antibody detection assays for COVID-19 diagnosis: an early overview. Immunol Cell Biol. https://doi.org/10.1007/s12251-020-00758-2

Fan H, Ooi A, Tan YW et al (2005) The nucleocapsid protein of coronavirus infectious bronchitis virus: crystal structure of its
n-terminal domain and multimerization properties. Structure 13:1859–1868. https://doi.org/10.1016/j.str.2005.08.021

Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses 128:2–1–23. https://doi.org/10.1007/978-1-4939-2436-7_1

Forrest LR, Tang CL, Honig B (2006) On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. Biophys J 91:508–517. https://doi.org/10.1529/biophysj.106.082313

Forster P, Forster L, Renfrew C, Forster M (2020) Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA 117:9241–9243. https://doi.org/10.1073/pnas.2004999117

Friedman M, Ratia K, Johnston RE et al (2009) Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IFR3 and NF-κB signaling. J Virol 83:6689–6705. https://doi.org/10.1128/JVI.02220-08

GISAID (2020) Genomic epidemiology of hCoV-19. https://www.gisaid.org. Accessed 25 Sept 2020

Gordon DE, Jang GM, Bouhaddou M et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459–468. https://doi.org/10.1038/s41586-020-2286-9

Guo L, Ren L, Yang S et al (2020) Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 71:778–785. https://doi.org/10.1093/cid/ciaa310

Habibzadeh P, Stoneman EK (2020) The novel coronavirus: a bird’s eye view. Int J Occup Environ Med 11:65–71. https://doi.org/10.15171/ijoem.2020.1921

Hassan SA, Sheikh FN, Jamal S et al (2020) Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. https://doi.org/10.7759/cureus.7355

Health C for D and R (2020) Coronavirus Disease 2019 (COVID-19) Emergency use authorizations for medical devices. In: FDA. https://www.fda.gov/medical-devices/emergency-use-authorizations-coronavirus-disease-2019-emergency-use-authorizations-medical-devices. Accessed 21 Dec 2020

Hellewell J, Abbott S, Gimma A et al (2020) Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 8:e488–e496. https://doi.org/10.1016/S2214-109X(20)30074-7

Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052

Horby P, Lim WS, Emberson JR et al (2020) Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2021436

Hosseiny M, Kooraki S, Gholamrezaezhad A et al (2020) Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome. Am J Roentgenol 214:1078–1082. https://doi.org/10.2214/AJR.20.22969

Huang C, Wang Y, Li X et al (2020a) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Huang Y, Yang C, Xu X et al (2020b) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 41:1141–1149. https://doi.org/10.1038/s41401-020-0485-4

Jacob JJ, Vasudevan K, Veeraraghavan B et al (2020) Genomic evolution of severe acute respiratory syndrome Coronavirus 2 in India and vaccine impact. Indian J Med Microbiol 38:210. https://doi.org/10.4103/ijmm.IJMM_20_303

James JA, André NM, Chappie JS et al (2020) Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop. J Mol Biol 432:3309–3325. https://doi.org/10.1016/j.jmb.2020.04.009

Jeon YJ, Yoo HM, Chung CH (2010) ISG15 and immune diseases. Biochim et Biophys Acta 1802:485–496. https://doi.org/10.1016/j.bbadis.2010.02.006

Jeronimo CMP, Farias MEL, Val FFA et al (2020) Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19: Metcovid): a randomized double-blind phase IIb placebo-controlled trial. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1177

Ji T, Liu Z, Wang G et al (2020) Detection of COVID-19: a review of the current literature and future perspectives. Biosens Bioelectron 166:112455. https://doi.org/10.1016/j.bios.2020.112455

Junier T, Zdobnov EM (2010) The Newick utilities: high-throughput phylogenetic tree processing in the Unix shell. Bioinformatics 26:1669–1670. https://doi.org/10.1093/bioinformatics/btq243

Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. https://doi.org/10.1093/molbev/msm010

Kilianski A, Mielech AM, Deng X, Baker SC (2013) Assessing activity and inhibition of middle east respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J Virol 87:11955–11962. https://doi.org/10.1128/JVI.02105-13

Klausegger A, Strobl A, Regl G et al (1999) Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. J Virol 73:3737–3743. https://doi.org/10.1128/JVI.73.5.3737-3743.1999

Ko W-C, Rolain J-M, Lee N-Y et al (2020) Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 55:105933. https://doi.org/10.1016/j.ijantimicag.2020.105933

Komander D, Clague MJ, Urbé S (2009) Breaking the chains: structural and function of the deubiquitinases. Nat Rev Mol Cell Biol 10:550–563. https://doi.org/10.1038/nrm2731

Koyama T, Platt D, Parida L (2020) Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ 98:495–504. https://doi.org/10.2471/BLT.20.253591

Kumar SU, Kumar DT, Christopher BP, Doss CGP (2020) The rise and impact of COVID-19 in India. Front Med. https://doi.org/10.3389/fmed.2020.00250

Kupferschmidt K, Cohen J (2020) WHO launches global megatrial of the four most promising coronavirus treatments. In: Science/AAAS. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments. Accessed 28 Dec 2020

Lai MM, Baric RS, Brayton PR, Stohlman SA (1984) Characterization of leader RNA sequences on the virion and mRNAs of mouse hepatitis virus, a cytoplasmic RNA virus. Proc Natl Acad Sci USA 81:3626–3630. https://doi.org/10.1073/pnas.81.12.3626

Lai MM, Baric RS, Makino S et al (1985) Recombination between nonsegmented RNA genomes of murine coronaviruses. J Virol 56:449–456. https://doi.org/10.1128/JVI.56.2.449-456.1985

Lambert-Niclot S, Cuffel A, Pape SL et al (2020) Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigens in nasopharyngeal swabs. J Clin Microbiol. https://doi.org/10.1128/JCM.00977-20

Lefort V, Desper R, Gascuel O (2015) FastME 2.0: a comprehensive, accurate, and fast distance-based phylogeny inference program.
Spaan W, Delius H, Skinner M et al (1983) Coronavirus mRNA synthesis involves fusion of non-contiguous sequences. EMBO J 2:1839–1844. https://doi.org/10.1002/j.1460-2075.1983.tb01667.x

Tang X, Wu C, Li X et al (2020) On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 7:1012–1023. https://doi.org/10.1093/nsr/nwaa036

Thirumal KD, Shaikh N, Udhaya Kumar S et al (2021) Structure-based virtual screening to identify novel potential compound as an alternative to remdesivir to overcome the RdRp protein mutations in SARS-CoV-2. Front Mol Biosci. https://doi.org/10.3389/fmolb.2021.645216

Thomas S (2020) The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathog Immun 5:342–363. https://doi.org/10.20411/pai.v5i1.377

Udhaya Kumar S, Thirumal Kumar D, Siva R, George Priya Doss C (2020) Kerala, India’s front runner in novel coronavirus disease (COVID-19). Front Med. https://doi.org/10.3389/fmed.2020.00355

van Boheemen S, de Graaf M, Lauber C et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. https://doi.org/10.1128/mBio.00473-12

Walls AC, Park Y-J, Tortorici MA et al (2020) Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein. Cell 181:281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058

Wang D, Hu B, Hu C et al (2020a) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069. https://doi.org/10.1001/jama.2020.1585

Zeng W, Liu G, Ma H et al (2020) Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun 527:618–623. https://doi.org/10.1016/j.bbrc.2020.04.136

Zhang C, Zheng W, Huang X et al (2020) Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1. J Proteome Res 19:1351–1360. https://doi.org/10.1021/acs.jproteome.0c00129

Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. PNAS 117:10970–10975. https://doi.org/10.1073/pnas.2005615117

Xu J, Zhao S, Teng T et al (2020) Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. https://doi.org/10.3390/v12020044

Yount B, Curtis KM, Baric RS (2000) Strategy for systematic assembly of large RNA and DNA genomes: transmissible gastroenteritis virus model. J Virol 74:10600–10611. https://doi.org/10.1128/JVI.74.22.10600-10611.2000

Zhang C, Zheng W, Huang X et al (2020) Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1. J Proteome Res 19:1351–1360. https://doi.org/10.1021/acs.jprot.0c00129

Zou L, Ruan F, Huang M et al (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179. https://doi.org/10.1056/NEJMc2001737